American Association For Cancer Research (original) (raw)
Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research ...
Nasdaq Globe Newswire 23 Apr 2026
TNX-1700 (TFF2-albumin fusion protein) reversed aging-associated gastric inflammation and significantly attenuated tumor progression in aged gastric microenvironment in preclinical models ... .
Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Form 8-K) (Tonix Pharmaceuticals Holding Corp)
Public Technologies 23 Apr 2026
at the American Association for Cancer Research (AACR) Annual Meeting 2026 ... at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22, 2026, in San Diego, California.
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research
Enid News & Eagle 20 Apr 2026
CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vivo models of ovarian, breast, and gastric cancers ... .
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting ...
Nasdaq Globe Newswire 20 Apr 2026
Monte Rosa Presents Preclinical Data at AACR 2026 on the Potential of its Cyclin E1 (CCNE1)-directed MGDs to Treat CCNE1-amplified Solid Tumors ... .
Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026 (Form 6-K) (Radiopharm Theranostics Ltd)
Public Technologies 20 Apr 2026
Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026.
Sapience Therapeutics Presents First Clinical Results from Phase 2 Study of ST316, First-in-Class β-catenin Antagonist, in Second-Line Colorectal Cancer at the American Association for Cancer Research (AACR) Annual Meeting 2026
PR Newswire 20 Apr 2026
... the presentation of new data on its clinical and pipeline programs at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026, in San Diego, California.
Therapies at American Association for Cancer Research (AACR) (Form 6-K) (Ascentage Pharma Group International)
Public Technologies 20 Apr 2026
Therapies at American Association for Cancer Research (AACR) ... poster format at the American Association for Cancer Research (AACR) 2026 Annual Meeting, held April 17 to 22, 2026 in San Diego, CA, USA.
Precision Biologics to Reveal New AML Target for CAR-NK at American Association for Cancer Research ...
Lebanon Express 18 Apr 2026
... in Acute Myeloid Leukemia (AML) for CAR-NK therapy.
Kalohexis Announces Poster Presentation at the American Association for Cancer Research Annual Meeting 2026
The Daily Record - Dunn 18 Apr 2026
NORTHBROOK, Ill., April 17, 2026 ....
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
Nasdaq Globe Newswire 17 Apr 2026
– Updated presentation on Cogent’s potent pan-KRAS(ON) inhibitor, CGT1263, showcasing its selectivity profile which could lead to reduction in skin toxicity associated with multi-RAS inhibitors ... .
Accent Therapeutics Presents Data Reinforcing Therapeutic Potential of Novel KIF18A Inhibitor, ATX-295, at the 2026 American Association for Cancer Research Annual Meeting
PR Newswire 17 Apr 2026
... data supporting its potentially best-in-class KIF18A inhibitor, ATX-295, at the American Association for Cancer Research (AACR) Annual Meeting 2026 taking place April 17-22 in San Diego, California.
Salubris Biotherapeutics Presents Phase 1/2 Dose Escalation and Expansion Cohort Data for JK06, 5T4-Targeted Antibody Drug Conjugate, at the American Association for Cancer Research Annual Meeting
Pharmiweb 17 Apr 2026
... non-small cell lung cancer (NSCLC) and breast cancer, which is being presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 on April 17-22, 2026 in San Diego, California.
Precision Biologics to Reveal New AML Target for CAR-NK at American Association for Cancer Research (AACR) Annual Meeting on April 19th, 2026
PR Newswire 17 Apr 2026
Recent data for several human AML subtypes expressing truncated core 1 O-glycans will be presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting on April 19th, 2026, in San Diego, CA, USA.
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting (Oric Pharmaceuticals Inc)
Public Technologies 17 Apr 2026
... American Association for Cancer Research (AACR) Annual Meeting highlighting the potential of rinzimetostat (ORIC-944), a potent and selective allosteric inhibitor of PRC2 to treat prostate cancer.
TRIANA Biomedicines Announces Oral Presentation of TRI-611 and Additional Poster Presentations at the American Association for Cancer Research Annual Meeting 2026
Pharmiweb 15 Apr 2026
... well as its preclinical asset Cyclin E1 (CCNE1) will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, California.